文献速递胸部肿瘤

组织和血液的基因组分析可预测已切除胸膜间皮瘤患者的生存结局

Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma.
PubMed 文献 · Eur J Cancer · 2023-11-20

该研究对12例已切除的IB-IIIB期胸膜间皮瘤患者的30份肿瘤组织及配对血浆样本行靶向二代测序,分析基因突变与预后的关联并在计算机中验证。结果显示高组织肿瘤突变负荷(>10个突变/Mb)、组织中位次要等位基因频率(>9个突变/Mb)、血液肿瘤突变负荷(>6个突变/Mb)及特定基因突变与更长的无病生存和/或总生存相关。组织与血液部分突变一致性>80%。

要点

  • 高组织TMB(>10个突变/Mb)、高组织MAF(>9个突变/Mb)、高血液TMB(>6个突变/Mb)与更长的无病生存和/或总生存相关。
  • 组织KMT2C、PBRM1、PKHD1、EPHB1及血液LIFR突变与更长的无病生存和/或总生存相关。
  • 组织与血液部分突变一致性>80%,分子谱分析或可识别已切除PM中的长期生存者。

核心结论

  • 组织TMB、组织MAF、血液TMB及特定突变与已切除胸膜间皮瘤患者的结局相关,应进一步研究以验证其作为预后生物标志物及潜在免疫检查点抑制剂联合治疗预测因素的作用。

研究设计与样本

  • 对12例已切除的IB-IIIB期胸膜间皮瘤患者的30份回顾性胸膜肿瘤组织及配对血浆样本行靶向二代测序。
  • 在计算机中验证预后与特定突变存在之间的关联。

主要发现

  • 高组织肿瘤突变负荷(>10个突变/Mb)与更长的无病生存和/或总生存相关。
  • 组织中位次要等位基因频率(>9个突变/Mb)与更长的无病生存和/或总生存相关。
  • 血液肿瘤突变负荷(>6个突变/Mb)与更长的无病生存和/或总生存相关。
  • 组织KMT2C、PBRM1、PKHD1、EPHB1及血液LIFR突变与更长的无病生存和/或总生存相关。
  • 部分突变在组织与血液间的一致性>80%。

关键数值与推荐

  • 高组织TMB阈值定为>10个突变/Mb。
  • 高组织MAF阈值定为>9个突变/Mb。
  • 高血液TMB阈值定为>6个突变/Mb。
  • 组织与血液部分突变一致性>80%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Pleural mesothelioma (PM) is an aggressive tumor still considered incurable, in part due to the lack of predictive biomarkers. Little is known about the clinical implications of molecular alterations in resectable PM tissues and blood. Here, we characterized genetic alterations to identify prognostic and predictive biomarkers in patients with resected PM. EXPERIMENTAL DESIGN: Targeted next-generation sequencing was performed in retrospective pleural tumor tissue and paired plasma samples from stage IB-IIIB resected PM. Association between prognosis and presence of specific mutations was validated in silico. RESULTS: Thirty PM tissues and paired blood samples from 12 patients were analyzed. High tissue tumor mutational burden (TMB) (>10 mutations/Mb), tissue median minor allele frequency (MAF) (>9 mutations/Mb), and blood TMB (>6 mutations/Mb), tissue KMT2C, PBRM1, PKHD1,EPHB1 and blood LIFR mutations correlated with longer disease-free survival and/or overall survival. High concordance (>80%) between tissue and blood was found for some mutations. CONCLUSIONS: Tissue TMB and MAF, blood TMB, and specific mutations correlated with outcomes in patients with resected PM and should be further studied to validate their role as prognostic biomarkers and potentially predictive factors for combinations with immune-checkpoint inhibitors. This suggest that molecular profiling could identify longer survivors in patients with resected PM.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. de Miguel-Perez D, Pickering EM, Malapelle U, et al. Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma. Eur J Cancer. 2023. PMID: 38008032. doi:10.1016/j.ejca.2023.113457

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。